CTRI/2024/02/062280
Not yet recruiting
Phase 3
Comparison of Efficacy and Safety of Subcutaneousversus Intramuscular Autologous Serum Therapy in Chronic SpontaneousUrticaria – A Randomized Controlled Study - NI
Mythraye B0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: L501- Idiopathic urticaria
- Sponsor
- Mythraye B
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients of age above 18 years clinically diagnosed
- •with chronic spontaneous urticaria and giving consent to participate in the
Exclusion Criteria
- •Pregnant and lactating women, immunocompromised
- •patients, those on immunosuppressants for other illness
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Evaluation of Efficacy and Safety of subcutaneous Remsima injection in Subjetcs with Active Ankylosing SpondylitisDiseases of the musculoskeletal system and connective tissueKCT0008747CHONNAM NATIONAL UNIVERSITY BITGOEUL HOSPITA60
Enrolling By Invitation
Not Applicable
Comparison of the clinical efficacy of subcutaneous versus oral administration of methotrexate in patients with psoriasis vulgarispsoriasis vulgarispsoriasis vulgaris,methotrexate,oral administration,subcutaneous injectionTCTR20190705002Faculty of Medicine80
Not yet recruiting
Phase 2
ESAR-814 StudyRheumatoid arthritis with moderate activityArthritis, RheumatoidArthritisJoint DiseasesRheumatic DiseasesMusculoskeletal DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System DiseasesRPCEC00000230Center for Genetic Engineering and Biotechnology (CIGB), in Havana196
Unknown
Phase 3
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (STATURE)JPRN-jRCT2080221733ovartis Pharma K.K.
Completed
Not Applicable
To evaluate the efficacy and safety of subcutaneous and intravenous abatacept.Rheumatoid arthritisJPRN-UMIN000013440Osaka Medical College50